Targeting a specific pathway in a rare type of kidney cancer
Targeting the CDK4/6 pathway in MiT/TFE-translocation renal cell carcinoma
['FUNDING_R21'] · DANA-FARBER CANCER INST · NIH-11032362
This study is looking at a rare and tough type of kidney cancer called translocation renal cell carcinoma (tRCC) to see if a certain pathway in cells can be targeted with existing medications to help slow down or stop the cancer from growing.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DANA-FARBER CANCER INST (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-11032362 on ClinicalTrials.gov |
What this research studies
This research focuses on translocation renal cell carcinoma (tRCC), a rare and aggressive form of kidney cancer that currently lacks targeted therapies. The study aims to explore the CDK4/6 pathway, which is crucial for cell proliferation, as a potential target for treatment. By using both genetic and pharmacologic methods, researchers will assess how effective inhibiting this pathway is in slowing down or stopping the growth of tRCC cells. The research will involve laboratory experiments and possibly animal models to evaluate the therapeutic potential of existing FDA-approved drugs that target this pathway.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with translocation renal cell carcinoma who have not responded to standard treatments.
Not a fit: Patients with other types of renal cell carcinoma or those whose cancer has progressed beyond the point of intervention may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options specifically designed for patients with translocation renal cell carcinoma.
How similar studies have performed: Previous research has shown promising results in targeting the CDK4/6 pathway in other cancers, suggesting potential for success in this novel application.
Where this research is happening
BOSTON, UNITED STATES
- DANA-FARBER CANCER INST — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: VISWANATHAN, SRINIVAS RAGHAVAN — DANA-FARBER CANCER INST
- Study coordinator: VISWANATHAN, SRINIVAS RAGHAVAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Breast Cancer